Compass Therapeutics

Yahoo Finance • 5 days ago

Compass Therapeutics to Participate in Upcoming December Investor Events

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will p... Full story

Yahoo Finance • 12 days ago

Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development

Compass Therapeutics Inc. (NASDAQ:CMPX) is a must-buy penny stock to buy now. On November 10, Pipe Sandler analyst Biren Amin reiterated that Compass Therapeutics Inc. (NASDAQ:CMPX) is a Buy and set a $12 price target. The positive stance... Full story

Yahoo Finance • 13 days ago

Eli Lilly inks $2.6B deal with South Korea's ABL Bio for bispecific antibodies

[3d rendering of Bispecific antibodies or BsAbs] Love Employee/iStock via Getty Images Eli Lilly has signed an agreement with ABL Biotech for access to the South Korean biotech's Grabody platform to develop bispecific antibodies that is w... Full story

Yahoo Finance • 25 days ago

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) an... Full story

Yahoo Finance • 3 months ago

Compass Therapeutics to Participate in Upcoming September Investor Events

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human dise... Full story

Yahoo Finance • 4 months ago

Compass Therapeutics prices $120 million public offering of common stock

BOSTON - Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage oncology-focused biopharmaceutical company with a market capitalization of $462 million and impressive year-to-date returns of 119%, announced Tuesday the pricing of an un... Full story

Yahoo Finance • 4 months ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human dise... Full story

Yahoo Finance • 4 months ago

Compass Therapeutics Announces Proposed Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human dise... Full story

Yahoo Finance • 4 months ago

Compass Therapeutics stock holds Outperform rating at Raymond James

Investing.com - Raymond James maintained its Outperform rating and $9.00 price target on Compass Therapeutics (NASDAQ:CMPX) following the company’s second-quarter financial results and clinical trial updates. The clinical-stage biopharmace... Full story

Yahoo Finance • 4 months ago

Tesla and Monday Lead Market Cap Stock Movers on Monday

Monday’s trading session has brought significant movements across the board, with Tesla Motors (NASDAQ:TSLA) accelerating upwards, while software company Monday (MNDY) experienced a steep drop. The market has reacted to a mix of earnings... Full story

Yahoo Finance • 4 months ago

Compass Therapeutics rises after pipeline updates

[Cancer cells vis] koto_feja Shares of Compass Therapeutics (NASDAQ:CMPX [https://seekingalpha.com/symbol/CMPX]) added ~21% on Monday after the cancer drug developer, with its Q2 2025 results, announced a lower-than-expected number of mor... Full story

Yahoo Finance • 4 months ago

Compass Therapeutics Inc (NASDAQ:CMPX) Reports Wider Q2 2025 Loss, Shares Show Mixed Reaction Amid Clinical Progress

COMPASS THERAPEUTICS INC (NASDAQ:CMPX [https://www.chartmill.com/stock/quote/CMPX]) REPORTS Q2 2025 RESULTS: WIDER LOSS THAN EXPECTED, MARKET SHOWS MIXED REACTION Compass Therapeutics Inc, a clinical-stage biopharmaceutical company focuse... Full story

Yahoo Finance • 4 months ago

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be... Full story

Yahoo Finance • 4 months ago

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for... Full story

Yahoo Finance • 4 months ago

Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top high-return penny stocks to buy now. On July 14, Stifel reiterated its Buy rating and $11.00 price target for CMPX. The firm views the extended timeline for topline data from the P... Full story

Yahoo Finance • 5 months ago

Stifel reiterates Buy rating on Compass Therapeutics stock with $11 target

Investing.com - Stifel maintained its Buy rating and $11.00 price target on Compass Therapeutics (NASDAQ:CMPX), currently trading at $2.92, following investor meetings with the company’s management team. The biotech company, with a market... Full story

Yahoo Finance • 7 months ago

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been d... Full story

Yahoo Finance • 8 months ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today... Full story

Yahoo Finance • 2 years ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Opened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients with advanced biliary tract cancers (BTC); top line data from this study is expected in... Full story

Yahoo Finance • 2 years ago

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today... Full story